Solventum (NYSE:SOLV) Issues FY 2026 Earnings Guidance

Solventum (NYSE:SOLV) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 7.100-7.200 for the period, compared to the consensus earnings per share estimate of 6.550. The company issued revenue guidance of -.

Analyst Ratings Changes

Several analysts recently weighed in on the company. BTIG Research lifted their price objective on Solventum from $91.00 to $95.00 and gave the company a “buy” rating in a report on Thursday. UBS Group upped their price target on shares of Solventum from $95.00 to $101.00 and gave the company a “buy” rating in a research note on Thursday. BMO Capital Markets started coverage on shares of Solventum in a report on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price target for the company. KeyCorp lifted their price objective on shares of Solventum from $93.00 to $102.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Piper Sandler boosted their price objective on shares of Solventum from $92.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday. Seven analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $91.64.

Solventum Price Performance

Shares of Solventum stock traded down $4.24 during trading hours on Thursday, reaching $83.23. 2,355,146 shares of the company’s stock were exchanged, compared to its average volume of 1,420,044. The business has a fifty day moving average of $79.24 and a two-hundred day moving average of $74.38. The company has a market capitalization of $14.41 billion, a P/E ratio of 10.20, a price-to-earnings-growth ratio of 1.36 and a beta of 0.60. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. Solventum has a 1 year low of $62.38 and a 1 year high of $90.00.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, beating the consensus estimate of $1.91 by $0.64. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same quarter in the previous year, the company earned $1.69 EPS. The business’s revenue for the quarter was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, research analysts predict that Solventum will post 6.58 earnings per share for the current fiscal year.

Solventum News Summary

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Solventum reported second-quarter adjusted EPS of $2.55, well above the $1.91 analyst consensus, while revenue of $2.21 billion exceeded the $2.15 billion estimate. Organic sales grew 9.5%, although reported revenue growth was 2.2% year over year. Solventum Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised its 2026 outlook, including adjusted EPS guidance to $7.10-$7.20, above the approximately $6.55-$6.58 consensus, and increased guidance for organic sales growth and free cash flow. Solventum outlines HIS separation and raises 2026 EPS guide
• Positive Sentiment: Piper Sandler, Wedbush and Stifel raised their price targets to $105, $101 and $100, respectively, maintaining bullish ratings ranging from overweight to buy. These targets imply substantial potential upside from recent trading levels. Analyst price-target updates
• Neutral Sentiment: Solventum plans to separate its Health Information Systems business, aiming to become a more focused medical-technology company while allowing the healthcare software unit to pursue its own growth strategy. The transaction could unlock value, but execution details and timing remain uncertain. Solventum to hive off healthcare software business
• Negative Sentiment: Management acknowledged that enterprise-resource-planning timing benefits contributed to the quarterly performance and guidance increase. Investors may therefore be questioning how much of the earnings beat reflects sustainable operating improvement versus temporary factors.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. State Street Corp increased its position in Solventum by 2.0% in the 4th quarter. State Street Corp now owns 6,344,761 shares of the company’s stock valued at $502,759,000 after acquiring an additional 124,490 shares during the period. Boston Partners increased its stake in Solventum by 26.1% in the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after purchasing an additional 959,543 shares in the last quarter. Invesco Ltd. boosted its position in shares of Solventum by 3.4% in the 4th quarter. Invesco Ltd. now owns 2,930,010 shares of the company’s stock worth $232,174,000 after buying an additional 96,236 shares in the last quarter. Morgan Stanley boosted its stake in shares of Solventum by 13.2% during the fourth quarter. Morgan Stanley now owns 1,660,906 shares of the company’s stock valued at $131,610,000 after acquiring an additional 193,154 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Solventum by 3.6% during the third quarter. Northern Trust Corp now owns 1,596,490 shares of the company’s stock worth $116,544,000 after buying an additional 56,146 shares during the period.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.